Home > Offer to Sell > Catalyst and Auxiliary > Other Auxiliary Agent > Orlistat Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-Tetrahydro
Orlistat Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-Tetrahydro
Inquiry
| Post Date: | Sep 08,2015 |
| Expiry Date: | Mar 06,2016 |
| Detailed Description: |
Orlistat
Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat CAS: 96829-58-2 MF: C29H53NO5 MW: 495.73 Product Categories: Pharmaceutical Raw Materials;Miscellaneous Biochemicals;Antiobesity Agent;Chiral Reagents;Pharmaceuticals Chemical Properties Off-White Solid Usage An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity. Packing:1kg/foil bag or as required 2. Description: Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Longterm use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively). |
| Company: | Shenzhen Simeiquan Bio-tech Co., Ltd. [ China ] |
| Contact: | sue@chembj.com |
| Tel: | +86-18038176812 |
| Fax: | +86-18038176812 |
| Email: | sue@chembj.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
